Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose.
OBJECTIVE
This study was conducted to determine the frequency of CYP2C9 alleles in Omani patients receiving warfarin and to correlate genotyping data with warfarin dosage. The Omani population has Asian and African ethnicities.


METHODS
CYP2C9 genotypes were determined by the polymerase chain reaction restriction fragment length polymorphism method. Non-parametric Kruskal-Wallis test was used to compare groups of continuous data for significance differences.


RESULTS
Genotyping data showed that 12.7 and 5.8% of the samples were heterozygous for the CYP2C9*2 and CYP2C9*3 alleles, respectively. The CYP2C9*2 allele frequency was 0.074 in our population. It was 0.029 for CYP2C9*3.


CONCLUSIONS
This is the first report on the presence of CYP2C9*2 allele homozygocity in any Asian or African population.
Tanira
Musbah O
MO
Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Al Khodh, Oman. tanira@squ.edu.om
Al-Mukhaini
Mohammed K
MK
Al-Hinai
Ali T
AT
Al Balushi
Khalid A
KA
Ahmed
Ikhlas S
IS
D000328:Adult; D000483:Alleles; D000925:Anticoagulants / Q000008:administration & dosage* / Q000378:metabolism; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009850:Oman; D010597:Pharmacogenetics; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D014859:Warfarin / Q000008:administration & dosage* / Q000378:metabolism
D000925:Anticoagulants; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases